Purpose: Alzheimer's disease is a neurodegenerative disease that begins before clinical symptoms emerge. Amyloid-beta plaques and tau neurofibrillary tangles are the hallmark lesions of Alzheimer's Disease (AD). Amyloid-beta plaques deposition is associated with increased hippocampal volume loss. The tissue volume measures reflect multiple underlying pathologies contributing to neurodegeneration, of which are the most characteristics of AD. Anatomical atrophy, as evidenced using Magnetic Resonance Imaging (MRI), is one of the most validated, easily accessible and widely used biomarkers of AD. Measurements of whole brain and hippocampal atrophy rates from serial structural MRI are potential markers of the underlying neuroaxonal damage and disease progression in AD. In this study, we extract automatically subcortical brain structures in AD and control subjects.
Introduction
Alzheimer's Disease (AD) is a neurodegenerative disease that begins before clinical symptoms emerge [1] . Amyloid-beta plaques and tau neurofibrillary tangles are the hallmark lesions of AD. Amyloid-beta plaques deposition is associated with increased hippocampal volume loss. The tissue volume measures reflect multiple underlying pathologies contributing to neurodegeneration, of which are the most characteristic of AD. Anatomical atrophy, as evidenced using Magnetic Resonance Imaging (MRI), is one of the most validated, easily accessible and widely used biomarkers of AD.
Measurements of whole brain and hippocampal atrophy rates from serial structural MRI are potential markers of the underlying neuroaxonal damage and disease progression in AD [2] [3] . AD involves significant impairments in many cognitive domains; failure of recent memory is usually the most prominent feature in the early stages of the disease. The primacy and prominence of memory impairment in AD is consistent with findings suggesting that neuropathological changes in the hippocampus and entorhinal cortex are the first and most severe to occur [4] . Involvement of these areas in AD leads to decrements in learning and memory during a preclinical phase of AD [5] . Hippocampal atrophy at the medial temporal lobe is therefore a site of early changes in AD. This can be visualised with high quality Magnetic Resonance (MR) Imaging. Hence, there is a role for volumetric measurement of the hippocampus in the earlier diagnosis of AD [6] . Quantification of the rate of global and regional brain volume loss from serially acquired MRI is increasingly used both to understand the progression of the disease and as an outcome measure for clinical trials [7] . In order to diagnose AD, we applied MRI volumetry approach for the hippocampus and cerebrum in an attempt to detect the changes of AD. The analysis of different brain structures separately is very useful in AD. Segmentation of structures such us cerebrum, cerebellum, brainstem, and brain hemispheres is of interest to assess brain asymmetry in AD subjects. The volumes of the hippocampi and the lateral ventricles have been shown to act as early biomarkers of AD. Hippocampus is involved in many brain functions such as memory and spatial reasoning. The study of the hippocampus volume is of great interest as it is a valuable tool for follow-up and treatment adjustment in AD. The analysis of the whole hippocampus is a consented approach to study AD [8] .
In this study, we extract automatically subcortical structure segmentation of AD and control subjects.
The rest of this paper is organised as follows: Section II is about subject recruitment, data acquisition and exploited method for brain volume segmentation, Section III describes the implementation and results, and Section IV concludes the delineates and summarises the future works.
Materials and Methods

2.1.Subjects
In this study we used 20 images (10 AD patients and 10 controls) taken from the Minimal Interval Resonance Imaging in Alzheimer's Disease (MIRIAD) dataset. MIRIAD is a series of longitudinal volumetric T1 MRI scans of AD patients and controls. All seen at the Dementia Research Centre, Institute of Neurology, UCL, and 23 nondemented control subjects, typically the patient's spouse or carer. Inclusion criteria included age over 55 years old and a Mini-Mental State Examination (MMSE) [9] score between 12/30 and 23/30 according to database. Controls had MMSE scores >26/30, and no history of cognitive impairment, head injury, major psychiatric disease or stroke. Exclusion criteria included any neurodegenerative disease (apart from AD for the patients), or inability to tolerate undergoing MRI.
2.2.MR Imaging
All subjects underwent MRI scanning on a 1.5 T Signa scanner (GE Medical Systems, Milwaukee, WI, USA) at baseline and at approximately 6 months and 12 months (mean[SD] intervals 180 [6] days; and 365 [10] days). T1weighted volumetric images were obtained using an inversion recovery prepared fast spoiled gradient echo sequence with acquisition parameters time to repetition = 15 ms, time to echo =5.4 ms, flip angle =15°, TI =650 ms, a 24-cm field of view and a 256 × 256 matrix, to provide 124 contiguous 1.5-mm thick slices in the coronal plane (voxels 0.9735 mm×0.9735 mm×1.5 mm) [11] .
2.3.Methods
We obtained volumes of Cerebrospinal Fluid (CSF), White Matter (WM), Grey Matter (GM), brain hemispheres, cerebellum and brainstem using volBrain pipeline, Figure 1 . [12] . This method is based on an advanced pipeline providing automatic segmentation of different brain structures from T1w MRI. The preprocessing is based on: (1) a denoising step with an adaptive non-local mean filter, (2) an affine registration in the Montreal Neurological Institute (MNI) space, (3) a correction of the image inhomogeneities, and (4) an intensity normalisation. Afterwards, MRI images were segmented in the MNI space using non-local patch-based multi-atlas method subcortical structure segments and related volumes and label maps information extracted. We compared left and right side of some of the important brain area in AD for obtaining a biomarker with brain atrophy.
The global GM, WM and CSF atrophy in AD are useful markers of disease progression in clinical trials. A method for quantifying GM, WM and CSF atrophy is segmentation and subtraction of serial GM, WM and CSF volumes. Images were corrected for intensity inhomogeneity using the N4 algorithm [13] , and the images were segmented into brain/nonbrain using a semiautomated technique (MIDAS). The non-local means filter [14] was used for each pixel in the image by computing a weighted average of surrounding pixels using a robust similarity measure that takes into account the neighbouring pixels surrounding the pixel being compared. Our segmentation method was based on the idea of non-local patch-based label fusion technique where patches of the subject to be segmented are compared with those of the training library [15] [16] . 
Results
We provided volume information of some macroscopic areas such as brain hemispheres, cerebellum and brainstem, Table 1 . Automatic subcortical structure segmentation is performed and related volumes and label maps were provided, Figure 2 ; also, segmented Cerebellum, white matter and lobules in T1 MRI, Figure  3 . Volumetry values were calculated through the hippocampus subfield segmentation and their asymmetries in MNI space, Figure 4 . 
Discussion
In our results, automated methods have shown better accuracy of brain segmentation can be used in classification of T1w MRI images into AD and HC. Out of the segmented brain areas, amygdala and caudate showed the greatest percentage difference between the two groups. The caudate volume 52% of whole brain in normal subjects changes into 37% in AD subjects that shown significant difference between two groups.
The volume of hippocampus is now considered as an important biomarker for AD. It has been shown that the hippocampal atrophy estimated on anatomical T1w MRI can help in classifying the different stages of AD [16] .
In this study, we proposed a method that combines a range of volumetric measurements, cortical thickness measurements, cerebellum, and hippocampal shape, to obtain a combination biomarker with main IntraCranial Cavity (ICC) tissues and hippocampus subfields that used more of the information contained in a structural MRI scan compared with a single biomarker approach.
Future research should investigate methods that are more robust and targeted to find brain areas that are indicative of different levels of cognitive impairments as measured by standardised methods such as MMSE. Furthermore, predictive methods should be devised to anticipate progress of the disease given MRI images taken in different time-points. 
